Bedel Financial Consulting, Inc. Ocuphire Pharma, Inc. Transaction History
Bedel Financial Consulting, Inc.
- $645 Million
- Q1 2024
A detailed history of Bedel Financial Consulting, Inc. transactions in Ocuphire Pharma, Inc. stock. As of the latest transaction made, Bedel Financial Consulting, Inc. holds 15,000 shares of OCUP stock, worth $23,250. This represents 0.0% of its overall portfolio holdings.
Number of Shares
15,000
Previous 15,000
-0.0%
Holding current value
$23,250
Previous $45,000
33.33%
% of portfolio
0.0%
Previous 0.01%
Shares
1 transactions
Others Institutions Holding OCUP
# of Institutions
52Shares Held
3.42MCall Options Held
3.6KPut Options Held
6.2K-
Vanguard Group Inc Valley Forge, PA992KShares$1.54 Million0.0% of portfolio
-
Rice Hall James & Associates, LLC292KShares$452,5760.04% of portfolio
-
Geode Capital Management, LLC Boston, MA234KShares$363,3160.0% of portfolio
-
Richmond Brothers, Inc. Jackson, MI227KShares$352,5640.87% of portfolio
-
Mai Capital Management224KShares$347,1530.0% of portfolio
About Ocuphire Pharma, Inc.
- Ticker OCUP
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 20,579,800
- Market Cap $31.9M
- Description
- Ocuphire Pharma, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of refractive and retinal eye disorders. Its lead product candidate is Nyxol eye drops, a once-daily preservative-free eye drop formulation of phentolamine mesylate, which is in Phase III clinical tr...